Melatonin augments apoptotic adipose-derived mesenchymal stem cell treatment against sepsis-induced acute lung injury

American Journal of Translational Research

Volumn 6, Issue 5, 2014, Pages 439-458

  Chen, Hong Hwa ^a   Chang, Chia Lo ^a   Lin, Kun Chen ^a   Sung, Pei Hsun ^a   Chai, Han Tan ^a   Zhen, Yen Yi ^a   Chen, Yi Ching ^a   Wu, Ying Chung ^a   Leu, Steve ^a   Tsai, Tzu Hsien ^a   Chen, Chih Hung ^a   Chang, Hsueh Wen ^b   Yip, Hon Kan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

Adipose derived mesenchymal stem cells; And melatonin; Inflammation; Oxidative stress; Reactive oxygen species; Sepsis induced organ injury

Indexed keywords

CD14 ANTIGEN; CD31 ANTIGEN; CD68 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; GELATINASE B; GLUTATHIONE PEROXIDASE; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1; MELATONIN; RANTES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SMAD1 PROTEIN; SMAD3 PROTEIN; SMAD5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ADIPOSE DERIVED MESENCHYMAL STEM CELL; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; APOPTOTIC ADIPOSE DERIVED STEM CELL; ARTICLE; BLOOD PRESSURE MEASUREMENT; CELL INFILTRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; LUNG PARENCHYMA; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; REGULATORY T LYMPHOCYTE; SEPSIS; SYSTOLIC BLOOD PRESSURE; WESTERN BLOTTING;

EID: 84908056416     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Cronshaw HL, Daniels R, Bleetman A, Joynes E and Sheils M. Impact of the Surviving Sepsis Campaign on the recognition and management of severe sepsis in the emergency department: are we failing? Emerg Med J 2011; 28: 670-675.
2. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL; International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
3. Grozdanovski K, Milenkovic Z, Demiri I and Spasovska K. Prediction of outcome from community-acquired severe sepsis and septic shock in tertiary-care university hospital in a developing country. Crit Care Res Pract 2012; 2012: 182324.
4. Tipler PS, Pamplin J, Mysliwiec V, Anderson D and Mount CA. Use of a protocolized approach to the management of sepsis can improve time to first dose of antibiotics. J Crit Care 2013; 28: 148-151.
5. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G., Carcillo J and Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.
6. Brun-Buisson C, Meshaka P, Pinton P, Vallet B; EPISEPSIS Study Group. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004; 30: 580-588.
7. Brun-Buisson C, Roudot-Thoraval F, Girou E, Grenier-Sennelier C and Durand-Zaleski I. The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis. Intensive Care Med 2003; 29: 1464-1471.
8. Hotchkiss RS and Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-150.
9. Hein F, Massin F, Cravoisy-Popovic A, Barraud D, Levy B, Bollaert PE and Gibot S. The relationship between CD4+CD25+CD127- regulatory T cells and inflammatory response and outcome during shock states. Crit Care 2010; 14: R19.
10. Taylor AL and Llewelyn MJ. Superantigen-induced proliferation of human CD4+CD25- T cells is followed by a switch to a functional regulatory phenotype. J Immunol 2010; 185: 6591-6598.
11. Venet F, Chung CS, Kherouf H, Geeraert A, Malcus C., Poitevin F, Bohe J, Lepape A, Ayala A and Monneret G. Increased circulating regulatory T cells (CD4(+)CD25(+)CD127(-)) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med 2009; 35: 678-686.
12. Venet F, Chung CS, Monneret G, Huang X, Horner B, Garber M and Ayala A. Regulatory T cell populations in sepsis and trauma. J Leukoc Biol 2008; 83: 523-535.
13. Fry DE. Sepsis, systemic inflammatory response, and multiple organ dysfunction: the mystery continues. Am Surg 2012; 78: 1-8.
14. Hartemink KJ and Groeneveld AB. The hemodynamics of human septic shock relate to circulating innate immunity factors. Immunol Invest 2010; 39: 849-862.
15. Maury E, Blanchard HS, Chauvin P, Guglielminotti J, Alzieu M, Guidet B and Offenstadt G. Circulating endotoxin and antiendotoxin antibodies during severe sepsis and septic shock. J Crit Care 2003; 18: 115-120.
16. Monserrat J, de Pablo R, Reyes E, Diaz D, Barcenilla H, Zapata MR, De la Hera A, Prieto A and Alvarez-Mon M. Clinical relevance of the severe abnormalities of the T cell compartment in septic shock patients. Crit Care 2009; 13: R26.
17. Galano A. On the direct scavenging activity of melatonin towards hydroxyl and a series of peroxyl radicals. Phys Chem Chem Phys 2011; 13: 7178-7188.
18. Galano A, Tan DX and Reiter RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51: 1-16.
19. Mauriz JL, Collado PS, Veneroso C, Reiter RJ and Gonzalez-Gallego J. A review of the molecular aspects of melatonin’s anti-inflammatory actions: recent insights and new perspectives. J Pineal Res 2013; 54: 1-14.
20. Zhang H, Liu D, Wang X, Chen X, Long Y, Chai W, Zhou X, Rui X, Zhang Q, Wang H and Yang Q. Melatonin improved rat cardiac mitochondria and survival rate in septic heart injury. J Pineal Res 2013; 55: 1-6.
21. Kesik V, Guven A, Vurucu S, Tunc T, Uysal B, Gundogdu G, Oztas E and Korkmaz A. Melatonin and 1400 W ameliorate both intestinal and remote organ injury following mesenteric ischemia/reperfusion. J Surg Res 2009; 157: e97-e105.
22. Patschan D, Hildebrandt A, Rinneburger J, Wessels JT, Patschan S, Becker JU, Henze E, Kruger A and Muller GA. The hormone melatonin stimulates renoprotective effects of “early outgrowth” endothelial progenitor cells in acute ischemic kidney injury. Am J Physiol Renal Physiol 2012; 302: F1305-1312.
23. Sahna E, Parlakpinar H, Turkoz Y and Acet A. Protective effects of melatonin on myocardial ischemia/reperfusion induced infarct size and oxidative changes. Physiol Res 2005; 54: 491-495.
24. Sener G, Sehirli AO, Keyer-Uysal M, Arbak S, Ersoy Y and Yegen BC. The protective effect of melatonin on renal ischemia-reperfusion injury in the rat. J Pineal Res 2002; 32: 120-126.
25. Leu S, Sun CK, Sheu JJ, Chang LT, Yuen CM, Yen CH, Chiang CH, Ko SF, Pei SN, Chua S, Youssef AA, Wu CJ and Yip HK. Autologous bone marrow cell implantation attenuates left ventricular remodeling and improves heart function in porcine myocardial infarction: an echocardiographic, six-month angiographic, and molecular-cellular study. Int J Cardiol 2011; 150: 156-168.
26. Yip HK, Chang LT, Wu CJ, Sheu JJ, Youssef AA, Pei SN, Lee FY and Sun CK. Autologous bone marrow-derived mononuclear cell therapy prevents the damage of viable myocardium and improves rat heart function following acute anterior myocardial infarction. Circ J 2008; 72: 1336-1345.
27. Chen YT, Sun CK, Lin YC, Chang LT, Chen YL, Tsai TH, Chung SY, Chua S, Kao YH, Yen CH, Shao PL, Chang KC, Leu S and Yip HK. Adipose-derived mesenchymal stem cell protects kidneys against ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. J Transl Med 2011; 9: 51.
28. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE and Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57: 11-20.
29. Maumus M, Guerit D, Toupet K, Jorgensen C and Noel D. Mesenchymal stem cell-based therapies in regenerative medicine: applica tions in rheumatology. Stem Cell Res Ther 2011; 2: 14.
30. Sun CK, Yen CH, Lin YC, Tsai TH, Chang LT, Kao YH, Chua S, Fu M, Ko SF, Leu S and Yip HK. Autologous transplantation of adipose-derived mesenchymal stem cells markedly reduced acute ischemia-reperfusion lung injury in a rodent model. J Transl Med 2011; 9: 118.
31. Thum T, Bauersachs J, Poole-Wilson PA, Volk HD and Anker SD. The dying stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle. J Am Coll Cardiol 2005; 46: 1799-1802.
32. Yip HK, Chang YC, Wallace CG, Chang LT, Tsai TH, Chen YL, Chang HW, Leu S, Zhen YY, Tsai CY, Yeh KH, Sun CK and Yen CH. Melatonin treatment improves adipose-derived mesenchymal stem cell therapy for acute lung ischemia-reperfusion injury. J Pineal Res 2013; 54: 207-221.
33. Chang CL, Leu S, Sung HC, Zhen YY, Cho CL, Chen A, Tsai TH, Chung SY, Chai HT, Sun CK, Yen CH and Yip HK. Impact of apoptotic adipose-derived mesenchymal stem cells on attenuating organ damage and reducing mortality in rat sepsis syndrome induced by cecal puncture and ligation. J Transl Med 2012; 10: 244.
34. Rittirsch D, Huber-Lang MS, Flierl MA and Ward PA. Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc 2009; 4: 31-36.
35. Zhu W, Chen J, Cong X, Hu S and Chen X. Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. Stem Cells 2006; 24: 416-425.
36. Reiter R, Tang L, Garcia JJ and Munoz-Hoyos A. Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sci 1997; 60: 2255-2271.
37. Reiter RJ, Melchiorri D, Sewerynek E, Poeggeler B, Barlow-Walden L, Chuang J, Ortiz GG and Acuna-Castroviejo D. A review of the evidence supporting melatonin’s role as an antioxidant. J Pineal Res 1995; 18: 1-11.
38. Reiter RJ, Tan DX, Osuna C and Gitto E. Actions of melatonin in the reduction of oxidative stress. A review. J Biomed Sci 2000; 7: 444-458.
39. Reiter RJ, Tan DX, Poeggeler B, Menendez-Pelaez A, Chen LD and Saarela S. Melatonin as a free radical scavenger: implications for aging and age-related diseases. Ann N Y Acad Sci 1994; 719: 1-12.